Less than three years after being set up, Germany's Immunic AG is merging with troubled Vital Therapies Inc. of the US, gaining a Nasdaq listing and a cash injection to advance its pipeline of oral inflammatory and autoimmune disease treatments.
The company, based in the Munich biotech hub of Martinsried, is benefiting from the demise of Vital, which went into...








